An observational study in COVID-19 and COVID-19 Pandemic, sponsored by Abionic SA. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-03.
Sponsored by Abionic SA · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 392 studies in COVID-19 with a site in Italy — 37 open to participants now, 46 under way, 7 of them phase 3. COVID-19 · Italy.
Among the 392 studies in COVID-19 with a site in Italy, this one is the 88th largest by enrollment of the 238 observational ones that give a count, is one of 36 that started in 2022, is one of 238 observational ones, and was the 328th registered.
7,993 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →37 of the 392 studies in COVID-19 with a site in Italy are open now. Recruiting first, the newest first:
Douglas D. Fraser · Sites in Italy, United States, Brazil and 4 more countries
Ages 18–65
Azienda USL Reggio Emilia - IRCCS · Sites in Italy
Ages 18–99 · Women only
Merck Sharp & Dohme LLC · Sites in Italy, United States, Argentina and 21 more countries
Ages 18+
IRCCS Sacro Cuore Don Calabria di Negrar · Sites in Italy
Ages 18+ · Healthy volunteers
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
392 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 53 · Phase 3 53 · Phase 4 3
First in 2009; this study’s year is marked. 36 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 440 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 100 across the 153 interventional studies, 251 across the 238 observational. Of the 235 that completed or were terminated, 29 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 392 have an industry lead sponsor. The 10 most frequent:
Abionic SA is the lead sponsor of 8 studies on the registry; none are open to participants now.
Abionic SA has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
7 of the studies in COVID-19 with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05587894ANRS, Emerging Infectious DiseasesOPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial | 2026-12-31 |
| NCT05188612University of BolognaInternational Survey of Acute Coronavirus Syndromes-COVID-19 | 2026-12-31 |
| NCT06070961Fondazione Italiana Linfomi - ETSProspective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance | 2027-05 |
Add all 7 to your calendar (.ics) → With an account.
Among the 392 studies in COVID-19 with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to conduct a prospective evaluation of the diagnostic performance of the IVD CAPSULE COVID-19-NP test for antigenic determination of SARS-CoV-2 virus on the abioSCOPE® instrument.
The objective of the clinical study is to demonstrate that the IVD CAPSULE COVID-19-NP test:
shows sensitivity:
The study population includes unselected participants*, symptomatic, asymptomatic having had close contact with positive patients, and asymptomatic with no known exposure to SARS-CoV-2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic performance of the IVD CAPSULE COVID-19-NP antigenic test
The purpose of this work is to carry out a prospective evaluation of the diagnostic performance of the IVD CAPSULE COVID-19-NP test for the antigenic determination of the SARS-CoV-2 virus on the abioSCOPE instrument.
Time frame: through study completion, an average of 1 month
Ran from Oct 2022 to primary completion in Jan 2023, 3 months.
Of 134 industry-sponsored observational studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 19. This study's 3 months is below that.
Counting every sponsor, half of 1,775 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abionic SA